LearnDrugs.com
Cardiovascular

Antiarrhythmics

High-yield Verified · Jul 2026

Prototype: amiodarone

Agents that modify cardiac conduction, grouped by the Vaughan-Williams classification (I–IV).

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 The heartbeat is electrical — the cardiac action potential

Every heartbeat starts as an electrical impulse. In each cardiac cell, ions flow across the membrane in a set sequence that makes up the action potential: sodium (Na⁺) rushes in to fire the impulse (depolarization), calcium (Ca²⁺) sustains it and drives contraction, and potassium (K⁺) flows out to reset the cell (repolarization). The pacemaker (SA node) sets the rate; the AV node gates how fast impulses pass to the ventricles.

An arrhythmia is this orderly sequence going wrong — the heart beating too fast, too slow, or chaotically (as in atrial fibrillation), often from an abnormal focus firing or an impulse looping back on itself (re-entry). Antiarrhythmics work by adjusting the very ion channels that shape the action potential.

The ions that build the cardiac action potential — each is a target for one antiarrhythmic class.

02 The four Vaughan-Williams classes

Antiarrhythmics are grouped by which ion channel they block — the Vaughan-Williams classification. Class I blocks sodium channels (slowing the initial upstroke; e.g. flecainide, lidocaine). Class II are the beta-blockers, which slow the SA/AV nodes via the sympathetic system. Class III blocks potassium channels, prolonging repolarization (e.g. sotalol, and amiodarone). Class IV are the non-dihydropyridine calcium channel blockers (diltiazem, verapamil), slowing AV conduction.

Amiodarone is the exception that proves the rule: it shows properties of all four classes at once. That broad action makes it highly effective — and, as the side effects show, uniquely toxic. Adenosine sits outside the classification: it briefly blocks the AV node to stop a re-entrant SVT.

Each class is defined by the ion channel it targets.

03 The paradox — and the price of amiodarone

Antiarrhythmics carry a built-in paradox: a drug that alters the heart’s electrical timing to *fix* one arrhythmia can create another. This is proarrhythmia. Class III agents (and others) prolong the QT interval, which can trigger a dangerous rhythm called torsades de pointes — so the QT is watched closely.

Amiodarone’s all-class potency comes at a cost seen nowhere else: because it is fat-soluble and stored in tissues with an extremely long half-life (weeks to months), it accumulates in the lungs (fibrosis), liver, thyroid (it is iodine-rich → hypo- or hyperthyroidism), eyes, and skin (blue-gray discoloration, photosensitivity). These slow, cumulative toxicities are the reason for its boxed warning and its intensive monitoring schedule.

Drug names

Generic Brand
amiodarone Pacerone, Cordarone
flecainide Tambocor
sotalololol Betapace
adenosine Adenocard

Indications

  • Atrial fibrillation / flutter (rate and rhythm control)
  • Ventricular tachycardia / fibrillation (amiodarone, lidocaine)
  • Termination of paroxysmal SVT (adenosine)

Mechanism of action

Alter cardiac ion channels and conduction per the Vaughan-Williams classes: I = sodium-channel blockers, II = beta-blockers, III = potassium-channel blockers (prolong repolarization), IV = non-dihydropyridine calcium channel blockers. Amiodarone shows properties of all four classes.

In plain terms
They steady the heart’s electrical signals to restore or keep a normal rhythm.

Therapeutic effects — what you'll see working

The goal is a stable rhythm at a safe rate — confirmed on the ECG/telemetry monitor, not by how the patient feels. Because these drugs can also *cause* arrhythmias, "success" always means watching the rhythm continuously.

Rhythm control Rate control Terminates SVT (adenosine)
Rhythm control
Restoring and maintaining normal sinus rhythm by damping abnormal foci or interrupting re-entry circuits — the aim in atrial fibrillation or ventricular tachycardia.
Rate control
Slowing AV-node conduction (class II and IV) to bring a rapid ventricular rate down to a safe range, even if the underlying rhythm remains abnormal.
Terminates SVT (adenosine)
A rapid IV push of adenosine briefly blocks the AV node — breaking the re-entrant loop of a paroxysmal SVT and often converting it back to sinus rhythm in seconds.

Adverse effects

Two themes run through the whole class: proarrhythmia (a rhythm drug can cause new rhythms, especially via QT prolongation) and, for amiodarone, cumulative multi-organ toxicity from tissue storage.

Caution: Common
Bradycardia, hypotension, dizziness, GI upset. Amiodarone: photosensitivity, blue-gray skin discoloration, corneal deposits.
Slowing conduction naturally tends toward bradycardia and hypotension. Amiodarone’s skin, corneal, and photosensitivity changes come from the drug depositing in tissues over time — cosmetic and usually reversible, but a visible clue the patient is accumulating drug.
Warning: Serious Report immediately
Proarrhythmia; QT prolongation → torsades de pointes (sotalol, class III); amiodarone thyroid dysfunction.
Proarrhythmia is the central danger — prolonging the QT interval can trigger torsades de pointes, a life-threatening ventricular rhythm, so a lengthening QT means reassess the drug. Because amiodarone is iodine-rich, it disrupts the thyroid, causing either hypo- or hyperthyroidism.
Black-box warning — most severe: ■ Boxed warning · amiodarone Report immediately
Potentially fatal pulmonary toxicity, hepatotoxicity, and proarrhythmia — reserve for life-threatening arrhythmias.
Amiodarone accumulates in the lungs and can cause pulmonary fibrosis / pneumonitis — a potentially fatal, sometimes irreversible scarring — along with hepatotoxicity and proarrhythmia. Because of this, it is reserved for life-threatening arrhythmias when safer agents have failed, and it requires scheduled lung, liver, thyroid, and eye monitoring.

Interactions

Digoxin drug
Amiodarone raises serum digoxin — reduce the digoxin dose and monitor levels.
Warfarin drug
Amiodarone raises warfarin levels → the INR rises — reduce the warfarin dose.
Other QT-prolonging drugs drug
Additive QT prolongation → torsades de pointes risk.

Contraindications

Contraindications are largely class-specific, but the shared theme is a heart that is already too slow or too blocked, or an ECG that is already primed for torsades.

2nd/3rd-degree AV block or sick sinus syndrome (without a pacemaker)
Most antiarrhythmics further slow conduction, which on top of an existing block can cause complete heart block.
Baseline QT prolongation (class III — sotalol, amiodarone)
These agents lengthen the QT further, sharply raising the risk of torsades de pointes.
Cardiogenic shock or severe bradycardia
Negative effects on rate, conduction, and contractility would worsen an already-compromised circulation.
Amiodarone: iodine hypersensitivity and thyroid disease use caution
Amiodarone is iodine-based and directly disrupts thyroid function, so pre-existing thyroid disease needs caution and monitoring.

Labs & levels

Test Therapeutic / normal Toxic / critical
TSH (thyroid function) Baseline & periodically — amiodarone is iodine-rich (hypo- or hyperthyroidism) Normal range 0.4–4.0 mIU/L
LFTs (hepatic function) Baseline & periodically — hepatotoxicity (boxed warning) Normal range AST 10–40 · ALT 7–56 U/L
Pulmonary — chest x-ray / PFTs Baseline — watch for pulmonary fibrosis / pneumonitis Normal range Clear CXR; normal DLCO at baseline
QT interval / ECG Continuous telemetry — a lengthening QT warns of torsades Normal range QTc < 450 ms (M) / < 460 ms (F) > 500 ms → torsades de pointes risk

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Monitoring
Keep the patient on continuous ECG / telemetry; monitor the QT interval, heart rate, and BP.
Why: These drugs can cause the very arrhythmias they treat; a lengthening QT is the early warning for torsades and prompts reassessment.
Amiodarone: obtain baseline and periodic pulmonary (PFTs / chest x-ray), liver (LFTs), thyroid (TSH), and eye exams.
Why: Amiodarone’s tissue accumulation causes slow, cumulative organ toxicity (the boxed warning) — scheduled monitoring catches it before it becomes irreversible.
Adenosine: give as a rapid IV push immediately followed by a saline flush; expect a brief pause/asystole.
Why: Adenosine’s half-life is only seconds, so it must reach the heart fast; the short pause is how it breaks the SVT and is expected.
Patient teaching
Amiodarone: use sun protection, and report a new cough or shortness of breath promptly.
Why: Photosensitivity causes severe sunburn; new respiratory symptoms may be early pulmonary toxicity, which must be caught quickly.
Understand amiodarone’s effects persist for weeks to months after stopping; attend all follow-up labs and ECGs and never adjust the dose independently.
Why: Its very long half-life means both benefit and toxicity linger, so monitoring continues even after discontinuation and dose changes must be supervised.

Sources

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.